Abstract 106P
Background
Polyps are considered as obligate precancerous disease. Different authors consider that percent of malignization ranges from 20% in single polyps to 95% in diffuse polyposis. Current research examines the results of the early diagnosis of colon cancer by using the biomarker CDKN2A for development of molecular-biological methods of prognostication.
Methods
Investigations were carried out in 30 patients during the period 2017-2019, the study included patients with single polyps, multiple polyps, polyposis of the colon, as well as patients without a history of neither familial nor sporadic cancer. 21 patients had polyposis, in 9 single colon polyps. The men were 19 women 11. The average age of patients was 52,4 ± 3,8 years. The levels of methylation of the gene CDKN2A were determined 18 patients. The material for the isolation of DNA was a serum obtained from venous blood and and biopsy material in amount of 50 mg. DNA extraction was held according to standards. After the conversion of DNA methyl-specific PCR was held.
Results
Among 30 patients with polyps and polyposis of the colon serum gene CDKN2A methylated DNA was detected in 18 patients. In 4 patients malignization of the polyp was determined. The volume of surgical intervention in patients with malignization was the same as cancer. It patients without malignization surgical intervention was limited with resection of the intestine without lymph dessection. In 8 patients the test result was negative. We did not perform surgical intervention to these patients they were sent to dynamic observation. Thus, the diagnostic efficacy in detection colorectal cancer in early diagnosis of by means of methylated DNA of the gene CDKN2A was - 60.1%.
Conclusions
If there is a positive test for methylation of the CDKN2A-gene, the risk of colorectal cancer is considered very high and these patients underwent surgical treatment. Application of molecular biological marker CDKN2A may be an effective method in early diagnosis of malignization of polyps. This method of diagnosis requires a more in-depth study, based on a study of a larger number of observations. Further investigations of the CDKN2a gene in ulcerative colitis, Krohn's disease, Lynch syndrome, Jeghers syndrome might be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NCC of Uzbekistan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract